Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
612 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peritoneal Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2015', provides an overview of the Peritoneal Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Peritoneal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peritoneal Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Peritoneal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peritoneal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Peritoneal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Peritoneal Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Peritoneal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Peritoneal Cancer Overview 11 Therapeutics Development 12 Pipeline Products for Peritoneal Cancer - Overview 12 Pipeline Products for Peritoneal Cancer - Comparative Analysis 13 Peritoneal Cancer - Therapeutics under Development by Companies 14 Peritoneal Cancer - Therapeutics under Investigation by Universities/Institutes 21 Peritoneal Cancer - Pipeline Products Glance 22 Late Stage Products 22 Clinical Stage Products 23 Early Stage Products 24 Peritoneal Cancer - Products under Development by Companies 25 Peritoneal Cancer - Products under Investigation by Universities/Institutes 32 Peritoneal Cancer - Companies Involved in Therapeutics Development 33 AbbVie Inc. 33 Acceleron Pharma, Inc. 34 Adaptimmune Limited 35 Advanced Accelerator Applications SA 36 Amgen Inc. 37 Array BioPharma Inc. 38 Astex Pharmaceuticals, Inc. 39 AstraZeneca Plc 40 Atara Biotherapeutics, Inc. 41 AVEO Pharmaceuticals, Inc. 42 Bayer AG 43 Beth Israel Deaconess Medical Center, Inc. 44 Bionomics Limited 45 Boehringer Ingelheim GmbH 46 Caladrius Biosciences, Inc. 47 Celldex Therapeutics, Inc. 48 Celsion Corporation 49 Cerulean Pharma, Inc. 50 Clovis Oncology, Inc. 51 Corcept Therapeutics Incorporated 52 Critical Outcome Technologies Inc. 53 CritiTech, Inc. 54 CTI BioPharma Corp. 55 Dr. Reddy's Laboratories Limited 56 EirGenix Inc. 57 Eli Lilly and Company 58 Epirus Biopharmaceuticals, Inc. 59 Exelixis, Inc. 60 F. Hoffmann-La Roche Ltd. 61 Galena Biopharma, Inc. 62 Genelux Corporation 63 Genentech, Inc. 64 Genor BioPharma Co., Ltd. 65 Glycotope GmbH 66 Gradalis Inc. 67 Hemispherx Biopharma, Inc. 68 Hetero Drugs Limited 69 ImmunoGen, Inc. 70 Immunovaccine, Inc. 71 Incyte Corporation 72 Innate Pharma SA 73 Johnson & Johnson 74 Kyowa Hakko Kirin Co., Ltd. 75 Lee's Pharmaceutical Holdings Limited 76 Mabion SA 77 MabVax Therapeutics Holdings, Inc. 78 MedImmune, LLC 79 Medivation, Inc. 80 Merck & Co., Inc. 81 Merrimack Pharmaceuticals, Inc. 82 Millennium Pharmaceuticals, Inc. 83 Mycenax Biotech Inc. 84 Novartis AG 85 Oasmia Pharmaceutical AB 86 OBI Pharma, Inc. 87 Oncobiologics, Inc. 88 Oncolytics Biotech Inc. 89 OncoMed Pharmaceuticals, Inc. 90 Oxford BioMedica Plc 91 OXiGENE, Inc. 92 Pharma Mar, S.A. 93 Pharmacyclics, Inc. 94 PsiOxus Therapeutics Limited 95 Quest PharmaTech Inc. 96 Recepta Biopharma S.A. 97 Sanofi Pasteur SA 98 Shenzen SiBiono GeneTech Co., Ltd 99 Sotio a.s. 100 Synta Pharmaceuticals Corp. 101 TapImmune Inc. 102 Tesaro, Inc. 103 TetraLogic Pharmaceuticals 104 Tyrogenex, Inc. 105 Vascular Biogenics Ltd. 106 VentiRx Pharmaceuticals, Inc. 107 Peritoneal Cancer - Therapeutics Assessment 108 Assessment by Monotherapy Products 108 Assessment by Target 109 Assessment by Mechanism of Action 116 Assessment by Route of Administration 121 Assessment by Molecule Type 123 Drug Profiles 125
List of Tables
Number of Products under Development for Peritoneal Cancer, H2 2015 20 Number of Products under Development for Peritoneal Cancer - Comparative Analysis, H2 2015 21 Number of Products under Development by Companies, H2 2015 23 Number of Products under Development by Companies, H2 2015 (Contd..1) 24 Number of Products under Development by Companies, H2 2015 (Contd..2) 25 Number of Products under Development by Companies, H2 2015 (Contd..3) 26 Number of Products under Development by Companies, H2 2015 (Contd..4) 27 Number of Products under Development by Companies, H2 2015 (Contd..5) 28 Number of Products under Investigation by Universities/Institutes, H2 2015 29 Comparative Analysis by Late Stage Development, H2 2015 30 Comparative Analysis by Clinical Stage Development, H2 2015 31 Comparative Analysis by Early Stage Development, H2 2015 32 Products under Development by Companies, H2 2015 33 Products under Development by Companies, H2 2015 (Contd..1) 34 Products under Development by Companies, H2 2015 (Contd..2) 35 Products under Development by Companies, H2 2015 (Contd..3) 36 Products under Development by Companies, H2 2015 (Contd..4) 37 Products under Development by Companies, H2 2015 (Contd..5) 38 Products under Development by Companies, H2 2015 (Contd..6) 39 Products under Investigation by Universities/Institutes, H2 2015 40 Peritoneal Cancer - Pipeline by AbbVie Inc., H2 2015 41 Peritoneal Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015 42 Peritoneal Cancer - Pipeline by Adaptimmune Limited, H2 2015 43 Peritoneal Cancer - Pipeline by Advanced Accelerator Applications SA, H2 2015 44 Peritoneal Cancer - Pipeline by Amgen Inc., H2 2015 45 Peritoneal Cancer - Pipeline by Array BioPharma Inc., H2 2015 46 Peritoneal Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 47 Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2 2015 48 Peritoneal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2015 49 Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2015 50 Peritoneal Cancer - Pipeline by Bayer AG, H2 2015 51 Peritoneal Cancer - Pipeline by Beth Israel Deaconess Medical Center, Inc., H2 2015 52 Peritoneal Cancer - Pipeline by Bionomics Limited, H2 2015 53 Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 54 Peritoneal Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015 55 Peritoneal Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 56 Peritoneal Cancer - Pipeline by Celsion Corporation, H2 2015 57 Peritoneal Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 58 Peritoneal Cancer - Pipeline by Clovis Oncology, Inc., H2 2015 59 Peritoneal Cancer - Pipeline by Corcept Therapeutics Incorporated, H2 2015 60 Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc., H2 2015 61 Peritoneal Cancer - Pipeline by CritiTech, Inc., H2 2015 62 Peritoneal Cancer - Pipeline by CTI BioPharma Corp., H2 2015 63 Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 64 Peritoneal Cancer - Pipeline by EirGenix Inc., H2 2015 65 Peritoneal Cancer - Pipeline by Eli Lilly and Company, H2 2015 66 Peritoneal Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 67 Peritoneal Cancer - Pipeline by Exelixis, Inc., H2 2015 68 Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 69 Peritoneal Cancer - Pipeline by Galena Biopharma, Inc., H2 2015 70 Peritoneal Cancer - Pipeline by Genelux Corporation, H2 2015 71 Peritoneal Cancer - Pipeline by Genentech, Inc., H2 2015 72 Peritoneal Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015 73 Peritoneal Cancer - Pipeline by Glycotope GmbH, H2 2015 74 Peritoneal Cancer - Pipeline by Gradalis Inc., H2 2015 75 Peritoneal Cancer - Pipeline by Hemispherx Biopharma, Inc., H2 2015 76 Peritoneal Cancer - Pipeline by Hetero Drugs Limited, H2 2015 77 Peritoneal Cancer - Pipeline by ImmunoGen, Inc., H2 2015 78 Peritoneal Cancer - Pipeline by Immunovaccine, Inc., H2 2015 79 Peritoneal Cancer - Pipeline by Incyte Corporation, H2 2015 80 Peritoneal Cancer - Pipeline by Innate Pharma SA, H2 2015 81 Peritoneal Cancer - Pipeline by Johnson & Johnson, H2 2015 82 Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 83 Peritoneal Cancer - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 84 Peritoneal Cancer - Pipeline by Mabion SA, H2 2015 85 Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 86 Peritoneal Cancer - Pipeline by MedImmune, LLC, H2 2015 87 Peritoneal Cancer - Pipeline by Medivation, Inc., H2 2015 88 Peritoneal Cancer - Pipeline by Merck & Co., Inc., H2 2015 89 Peritoneal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2015 90 Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 91 Peritoneal Cancer - Pipeline by Mycenax Biotech Inc., H2 2015 92 Peritoneal Cancer - Pipeline by Novartis AG, H2 2015 93 Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2015 94 Peritoneal Cancer - Pipeline by OBI Pharma, Inc., H2 2015 95 Peritoneal Cancer - Pipeline by Oncobiologics, Inc., H2 2015 96 Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 97 Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H2 2015 98 Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H2 2015 99 Peritoneal Cancer - Pipeline by OXiGENE, Inc., H2 2015 100 Peritoneal Cancer - Pipeline by Pharma Mar, S.A., H2 2015 101 Peritoneal Cancer - Pipeline by Pharmacyclics, Inc., H2 2015 102 Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015 103 Peritoneal Cancer - Pipeline by Quest PharmaTech Inc., H2 2015 104 Peritoneal Cancer - Pipeline by Recepta Biopharma S.A., H2 2015 105 Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2 2015 106 Peritoneal Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015 107 Peritoneal Cancer - Pipeline by Sotio a.s., H2 2015 108 Peritoneal Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 109 Peritoneal Cancer - Pipeline by TapImmune Inc., H2 2015 110 Peritoneal Cancer - Pipeline by Tesaro, Inc., H2 2015 111 Peritoneal Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2015 112 Peritoneal Cancer - Pipeline by Tyrogenex, Inc., H2 2015 113 Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd., H2 2015 114 Peritoneal Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 115 Assessment by Monotherapy Products, H2 2015 116 Number of Products by Stage and Target, H2 2015 118 Number of Products by Stage and Mechanism of Action, H2 2015 125 Number of Products by Stage and Route of Administration, H2 2015 130 Number of Products by Stage and Molecule Type, H2 2015 132 Peritoneal Cancer Therapeutics - Recent Pipeline Updates, H2 2015 388 Peritoneal Cancer - Dormant Projects, H2 2015 601 Peritoneal Cancer - Dormant Projects (Contd..1), H2 2015 602 Peritoneal Cancer - Dormant Projects (Contd..2), H2 2015 603 Peritoneal Cancer - Discontinued Products, H2 2015 604
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
